105 research outputs found
Developmental Failure and Loss of Reproductive Capacity as a Factor in Extinction: A Nine-Year Study of Dedeckera Eurekensis (Polygonaceae)
Many long-lived perennial species exhibit lowered reproductive capacity. Early studies of reproductive success in Dedeckera eurekensis (Polygonaceae) demonstrated that the species exhibited extremely low reproductive success, low seed/ovule (S/O) ratios (i.e., the percentage of ovules that produce filled seeds; 2.5 %), low germinability of filled seeds (3.5%), low seedling survivorship (11 .1%), and lack of recruitment in natural populations. These results were attributed to genetic load, but this elicited controversy, prompting long-term studies of the relationship between the S/O ratio and environment. After nine years of monitoring, however, the S/O ratio had not changed significantly (2 .7%), and there was no significant correlation between precipitation and the S/O ratio. Controlled field experiments demonstrated that neither resource availability nor other ecological factors significantly influenced embryo abortion rates. Controlled self-pollinations (N = 115) matured only one questionably filled seed, whereas intrapopulation cross-pollinations (N = 192) produced significantly more seed (S/O = 12.0 %). Previous pollination studies demonstrated that the species has no primary pollinators and is only rarely visited by a few generalist insects. However, the flowers typically self-pollinate in 2—3 days following anthesis. Strong inference suggests that the loss of reproductive capacity in D. eurekensis may be the result of inbreeding depression due to the superimposition of self-pollination on a normally outcrossed species carrying a high genetic/segregational load
An improved content search engine. Usage of network configuration information
科研費報告書収録論文(課題番号:09680388・基盤研究(C)(2)・H9~H10/研究代表者:根元, 義章/情報フィルタリングを用いた大規模情報ネットワークのリアルタイム障害検出方式
Validation of a Multivariate Serum Profile for Epithelial Ovarian Cancer Using a Prospective Multi-Site Collection
In previous studies we described the use of a retrospective collection of ovarian cancer and benign disease samples, in combination with a large set of multiplexed immunoassays and a multivariate pattern recognition algorithm, to develop an 11-biomarker classification profile that is predictive for the presence of epithelial ovarian cancer. In this study, customized, Luminex-based multiplexed immunoassay kits were GMP-manufactured and the classification profile was refined from 11 to 8 biomarkers (CA-125, epidermal growth factor receptor, CA 19-9, C-reactive protein, tenascin C, apolipoprotein AI, apolipoprotein CIII, and myoglobin). The customized kits and the 8-biomarker profile were then validated in a double-blinded manner using prospective samples collected from women scheduled for surgery, with a gynecologic oncologist, for suspicion of having ovarian cancer. The performance observed in model development held in validation, demonstrating 81.1% sensitivity (95% CI 72.6 – 87.9%) for invasive epithelial ovarian cancer and 85.4% specificity (95% CI 81.1 – 88.9%) for benign ovarian conditions. The specificity for normal healthy women was 95.6% (95% CI 83.6 – 99.2%). These results have encouraged us to undertake a second validation study arm, currently in progress, to examine the performance of the 8-biomarker profile on the population of women not under the surgical care of a gynecologic oncologist
Pregnancy and neonatal outcomes of COVID-19: The PAN-COVID study
Objective
To assess perinatal outcomes for pregnancies affected by suspected or confirmed SARS-CoV-2 infection.
Methods
Prospective, web-based registry. Pregnant women were invited to participate if they had suspected or confirmed SARS-CoV-2 infection between 1st January 2020 and 31st March 2021 to assess the impact of infection on maternal and perinatal outcomes including miscarriage, stillbirth, fetal growth restriction, pre-term birth and transmission to the infant.
Results
Between April 2020 and March 2021, the study recruited 8239 participants who had suspected or confirmed SARs-CoV-2 infection episodes in pregnancy between January 2020 and March 2021.
Maternal death affected 14/8197 (0.2%) participants, 176/8187 (2.2%) of participants required ventilatory support. Pre-eclampsia affected 389/8189 (4.8%) participants, eclampsia was reported in 40/ 8024 (0.5%) of all participants.
Stillbirth affected 35/8187 (0.4 %) participants. In participants delivering within 2 weeks of delivery 21/2686 (0.8 %) were affected by stillbirth compared with 8/4596 (0.2 %) delivering ≥ 2 weeks after infection (95 % CI 0.3–1.0). SGA affected 744/7696 (9.3 %) of livebirths, FGR affected 360/8175 (4.4 %) of all pregnancies.
Pre-term birth occurred in 922/8066 (11.5%), the majority of these were indicated pre-term births, 220/7987 (2.8%) participants experienced spontaneous pre-term births. Early neonatal deaths affected 11/8050 livebirths. Of all neonates, 80/7993 (1.0%) tested positive for SARS-CoV-2.
Conclusions
Infection was associated with indicated pre-term birth, most commonly for fetal compromise. The overall proportions of women affected by SGA and FGR were not higher than expected, however there was the proportion affected by stillbirth in participants delivering within 2 weeks of infection was significantly higher than those delivering ≥ 2 weeks after infection. We suggest that clinicians’ threshold for delivery should be low if there are concerns with fetal movements or fetal heart rate monitoring in the time around infection
Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications
This work was supported by a restricted research grant of Bayer AG
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two
Background
The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd.
Methods
We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background.
Results
First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001).
Conclusions
In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival
Representing Network Config Info in the Directory
In this paper two naming schemes for the X.500 Directory are proposed. One proposal (Network Elements) concernes the representation of computer networks, the other (IP namespace) provides a mapping algorithm for IP addresses to nodes. 1 Network Elements For representing networks in the Directory we model a network as follows. A network comprises of : 1. a possibly null set of nodes, 2. a possibly null set of lines, 3. a possibly null set of (sub)networks. Basically, the objects and attributes proposed here are an extension to RFC 1279 ([HK 91]). Information about networks is kept in the DIT as subordinate of the organization maintaining the network. There is one network object giving general descriptions of the network. Subordinates of this network object are node and line objects for each element present in the network. A network can be physically or logically subdivided into several (sub)networks. In this case, a network entry will have network objects as subordinates which themselve..
- …